[5-Methoxy-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]boronic acid | 348640-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: [5-Methoxy-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]boronic acid
• CAS: 348640-19-7
• 化学式: C₁₄H₁₈BNO₅
• 分子量: 291.112
• InChiKey: HVQUTNWOXNKNEK-UHFFFAOYSA-N

物化性质

• 密度：
  1.19

计算性质

• 辛醇/水分配系数(LogP)：
  1.11
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  80.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [5-Methoxy-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]boronic acid 在 potassium phosphate 、 三溴化硼 、 copper dichloride 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 44.0h， 生成 scalaridine A
  参考文献：
  名称：

  铜催化的见解：铃木-宫浦的芳基/吲哚基硼酸酯交叉偶联中原位形成的纳米Cu 2 O

  摘要：

  已经研究了无配体铜催化3,5-二碘吡啶与芳基和吲哚硼酸酯的Suzuki-Miyaura偶联，收率良好。原位生成的纳米铜的2从氯化亚铜ø 2在反应条件下已经发现首次。通过5-碘嘧啶，碘吡啶，碘苯和二碘苯的芳基化进一步证明了反应的一般性，并产生了良好至中等的收率。此外，双吲哚生物碱Scalaridine A已成功地以60％的总收率合成。

  DOI：

  10.1021/acs.orglett.7b01669
• 作为产物：
  描述：

  3-碘-5-甲氧基吲哚-1-羧酸叔丁酯 在 正丁基锂 、 硼酸三甲酯 作用下， 生成 [5-Methoxy-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]boronic acid
  参考文献：
  名称：

  Design of Potent IGF1-R Inhibitors Related to Bis-azaindoles

  摘要：

  From an azaindole lead, identified in high throughput screen, a series of potent bis‐azaindole inhibitors of IGF1‐R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis. Although the resulting compounds produced the expected improved potency, the model was not validated by the co‐crystallization experiments with IGF1‐R.

  DOI：

  10.1111/j.1747-0285.2010.00991.x

文献信息

• Azaindoles
  申请人：——

  公开号：US20040009983A1

  公开（公告）日：2004-01-15

  The invention is directed to compositions containing physiologically active compounds of general formula (I): 1 wherein R 1 is aryl or heteroaryl; R 2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, —Z 1 R 8 , —C(═O)—NY 3 Y 4 , —CO 2 R 8 , —NY 3 Y 4 , —N(R 6 )—C(═O)—R 7 , —N(R 6 )—C(═O)—NY 3 Y 4 , —N(R 6 )—C(═O)—OR 7 , —N(R 6 )—SO 2 —R 7 , —N(R 6 )—SO 2 —NY 3 Y 4 and one or more halogen a toms ; R 3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, —C(═O)—OR 5 or —C(═O)—NY 3 Y; and X 1 represents N, CH, C-halo, C—CN, C—R 7 , C—NY 3 Y 4 , C—OH, C—Z 2 R 7 , C—C(═O)—OR 5 , C—C(═O)—NY 3 Y 4 , C—N(R 8 )—C(═O)—R 7 , C—SO 2 —NY 3 Y 4 , C—N(R 8 )—SO 2 —R 7 , C-alkenyl, C-alkynyl or C—NO 2 ; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.

  这项发明涉及含有一般式（I）中生理活性化合物的组合物：其中R1为芳基或杂芳基；R2代表氢、酰基、氰基、卤素、可选择地由氰基、杂芳基、杂环烷基、—Z1R8、—C（═O）—NY3Y4、—CO2R8、—NY3Y4、—N(R6)—C（═O）—R7、—N(R6)—C（═O）—NY3Y4、—N(R6)—C（═O）—OR7、—N(R6)—SO2—R7、—N(R6)—SO2—NY3Y4和一个或多个卤原子取代的较低烯基或较低烷基；R3代表氢、芳基、氰基、卤素、杂芳基、较低烷基、—C（═O）—OR5或—C（═O）—NY3Y；X1代表N、CH、C-卤素、C—CN、C—R7、C—NY3Y4、C—OH、C—Z2R7、C—C（═O）—OR5、C—C（═O）—NY3Y4、C—N(R8)—C（═O）—R7、C—SO2—NY3Y4、C—N(R8)—SO2—R7、C-烯基、C-炔基或C—NO2；以及它们的前药、这些化合物及其前药的药学上可接受的盐和溶剂，以及在一般式（I）范围内的新化合物。这些化合物和组合物具有有价值的药物特性，特别是抑制蛋白激酶的能力。
• Insight into Copper Catalysis: In Situ Formed Nano Cu₂O in Suzuki–Miyaura Cross-Coupling of Aryl/Indolyl Boronates
  作者：Ganapathy Ranjani、Rajagopal Nagarajan

  DOI：10.1021/acs.orglett.7b01669

  日期：2017.8.4

  aryl and indole boronates has been explored in good to excellent yields. In situ generation of nano-Cu2O from CuCl2 under the reaction conditions has been discovered for the first time. The generality of the reaction was further demonstrated by the arylation of 5-iodopyrimidine, iodopyridines, iodobenzenes, and diiodobenzenes and resulted in good to moderate yields. Moreover, bisindole alkaloid Scalaridine

  已经研究了无配体铜催化3,5-二碘吡啶与芳基和吲哚硼酸酯的Suzuki-Miyaura偶联，收率良好。原位生成的纳米铜的2从氯化亚铜ø 2在反应条件下已经发现首次。通过5-碘嘧啶，碘吡啶，碘苯和二碘苯的芳基化进一步证明了反应的一般性，并产生了良好至中等的收率。此外，双吲哚生物碱Scalaridine A已成功地以60％的总收率合成。
• Design of Potent IGF1-R Inhibitors Related to Bis-azaindoles
  作者：Conception Nemecek、William A. Metz、Sylvie Wentzler、Fa-Xiang Ding、Corinne Venot、Catherine Souaille、Anne Dagallier、Sébastien Maignan、Jean-Pierre Guilloteau、François Bernard、Alain Henry、Sandrine Grapinet、Dominique Lesuisse

  DOI：10.1111/j.1747-0285.2010.00991.x

  日期：——

  From an azaindole lead, identified in high throughput screen, a series of potent bis‐azaindole inhibitors of IGF1‐R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis. Although the resulting compounds produced the expected improved potency, the model was not validated by the co‐crystallization experiments with IGF1‐R.